Financial Performance Summary
Neuland Laboratories announced financial results for the quarter ended June 30, 2026 (Q1 FY27). The company reported significant year-over-year growth but sequential decline from the previous quarter.
Key Financial Metrics (Rs. crore):
| Metric | Q1FY27 | Q1FY26 | YoY Change | Q4FY26 | QoQ Change |
| Total Income | 650.1 | 300.6 | +116.3% | 788.7 | -17.6% |
| EBITDA | 231.1 | 42.1 | +448.2% | 319.4 | -27.6% |
| EBITDA Margin | 35.5% | 14.0% | +2150 bps | 40.5% | -500 bps |
| Profit Before Tax | 197.5 | 17.4 | +1036.7% | 287.0 | -31.2% |
| PBT Margin | 30.4% | 5.8% | +2460 bps | 36.4% | -601 bps |
| Profit After Tax | 147.4 | 13.7 | +975.0% | 212.5 | -30.6% |
| PAT Margin | 22.7% | 4.6% | +1811 bps | 26.9% | -423 bps |
| EPS (Rs.) | 114.9 | 10.7 | +975.0% | 165.6 | -30.6% |
Performance Drivers and Business Update
The company reported encouraging performance from both CMS (Custom Manufacturing Solutions) and GDS businesses. Commercial Products contributed to most of the revenue, and the company is seeing exciting developments in pipeline projects.
Management commentary indicated that customer conversations have significantly strengthened, with broader capability-led discussions rather than individual projects alone. The focus is on delivering consistently, building customer confidence, and establishing foundations for long-term partnerships.
Capital Expenditure and Investments
The company has invested significantly over the last three years, with all significant Capex projects proceeding according to plan. Management believes the intensity of investments will further increase based on available opportunities.
Upcoming Events
The company will conduct an earnings call at 17:30 hrs IST on Wednesday, August 5, 2026, where management will discuss performance and answer participant questions. The transcript will be uploaded to the company website in due course.
Company Background
Neuland Laboratories is a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and custom manufacturing solutions services to customers in approximately 80 countries. The company has developed more than 300 processes and 100 APIs, with around 1010+ Regulatory filings across various geographies including 75 active US DMFs.